Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribavirin in eIF4E-Overexpressing Solid Tumors
NCT01309490Phase 2Terminated
- Sponsor
- Jewish General Hospital
- Start
- Mar 2011
- Primary completion
- Oct 2014
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of ribavirin in solid tumor, breast cancer, head and neck squamous cell carcinoma (HNSCC), sponsored by Jewish General Hospital. Started Mar 2011; status: terminated.
02
Drugs
ribavirin
03
Conditions
solid tumorbreast cancerhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01309490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01309490.